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Title: Lung Cancer Stigma: A Concept with consequences for patients 
ABSTRACT 
Background: Patients with lung cancer (LC) report lower quality of life (QoL) and higher levels of 
psychological distress compared to other cancer populations. Lung cancer stigma (LCS) may in part 
explain these findings. Aim: We investigated the prevalence of patient-perceived lung cancer stigma 
(LCS) and its relationships to symptom burden/severity, depression, and deficits in health-related 
quality of life (HR-QoL). Methods: In this descriptive, observational and cross-sectional study, 201 
participants were sent questionnaires. These included The Cataldo Lung Cancer Stigma Scale 
(CLCSS); the Lung Cancer Symptom Scale; the Centre for Epidemiologic Studies-Depression Scale; 
and the Quality of Life Inventory. Results: Participants were on average 69 years old, 52% women, 
95% ever smokers, and 18.5% current smokers. The mean total CLCSS score was 53.1 (SD=14.1; 
range=31-94). LCS was significantly correlated with younger age (p<0.001), greater social 
deprivation (p<0.05), being unemployed (p<0.001), depression (p<0.001), symptom burden 
(p<0.001), and HR-QoL deficits (p<0.001). Symptom burden explained 18% of variance in LCS 
(p<0.001). LCS explained 8.5% and 14.3% of the variance in depression (p<0.001) and HR-QoL 
(p<0.001), respectively. Conclusion: Patients with lung cancer are vulnerable to LCS. Symptom 
burden can directly contribute to greater perceived LCS. Greater perceived LCS can be directly 
related to greater levels of depression and lower HR-QoL. A tailored approach is required to screen 
for LCS and implement interventions to enhance the psycho-social well-being of patients with 
perceived LCS.  
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important to understand the effects of perceived LCS in a UK sample to inform healthcare providers 
INTRODUCTION 
Compared to patients with a history of other cancers, patients with lung cancer (LC) are more likely to 
report only fair or poor health, and exhibit significant psychological problems (Hewitt, Rowland, & 
Yancik, 2003). Psychological morbidity has been associated with increased symptom burden and lack 
of social support (Sullivan et al., 2016), being the precursor of poor health-related quality of life (HR-
QoL) and increased risk for mortality (Satin, Linden, & Phillips, 2009). Specific to lung cancer, up to 
55% of patients may meet the criteria for clinical depression (Cataldo & Brodsky, 2013). In addition, 
the association between depression and mortality is stronger among patients exhibiting more 
symptoms and those who report less social support (Sullivan et al., 2016).  
Psychological morbidity in patients with lung cancer may have its origins in perceived lung cancer 
stigma (LCS). In his classic work about stigma, Goffman (2009) defined stigma as “an attribute that is 
deeply discrediting”. This can result in patients feeling unjustly blamed for their illness and 
particularly stigmatised because the disease is so strongly associated with smoking (Chapple, 
Ziebland, & McPherson, 2004; Sasco, Secretan, & Straif, 2004). Blame has often been cited as a 
major stressor of having lung cancer (Marlow, Waller, & Wardle, 2010; Taylor et al., 2008). Indeed, 
patients with lung cancer are more likely to report internal causal attributions for their cancer than 
patients with breast or prostate cancer (Else-Quest, LoConte, Schiller, & Hyde, 2009). Previous US-
based research has demonstrated a link between LCS and poor patient outcomes. Specifically, LCS 
was associated with greater depressive symptomatology (Brown Johnson, Brodsky, & Cataldo, 2014; 
Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011; Gonzalez & Jacobsen, 2012), poorer HR-QoL 
(Cataldo et al., 2011), and higher symptom severity (Cataldo & Brodsky, 2013). Furthermore, LCS 
was found to account for unique and significant variability of 5%, 1.2% and 1.3% in depression 
(Gonzalez & Jacobsen, 2012), HR-QoL (Brown Johnson et al., 2014), and symptom severity (Cataldo 
& Brodsky, 2013), respectively.  
Health-related stigma is a culturally derived phenomenon (Van Brakel, 2006). Therefore, it is 
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We specifically hypothesised that greater symptom burden and/or severity would be adversely related 
to greater perceived LCS. In turn, greater perceived LCS would be associated with greater levels of 
depression and lower HR-QoL. 
1. What is the prevalence and are the characteristics of perceived LCS in LC patients in Scotland?
2. What are the effects of lung cancer symptom severity and/or burden on perceived LCS,
controlling for patient socio-demographic characteristics and clinical variables?
3. What are the effects of perceived LCS on depression, controlling for patient socio-
demographic characteristics and clinical variables?
4. What are the effects of perceived LCS on HR-QoL, controlling for patient socio-demographic
characteristics and clinical variables?
of the needs of their patients with the intention to develop support pathways for these patients.  To 
date, studies that quantify LCS is limited to studies from the USA, and Australia (Brown & Cataldo, 
2013; Brown Johnson et al., 2014; Cataldo & Brodsky, 2013; Cataldo, Jahan, & Pongquan, 2012; 
Chambers, Baade, et al., 2015; Rose et al., 2018). No research has been conducted in the United 
Kingdom to explore LCS and its relationship with symptom burden/severity, depression, and HR-
QoL. Investigating and understanding these relationships is a necessary first step to facilitate the 
development of possible targeted LCS interventions. This study aimed to address this existing gap in 
knowledge in the UK as follows.  
Aims and Hypothesis 
Our aim was to investigate the prevalence of patient-perceived LCS, and the role of LCS as a 
covariate of symptom severity and/or burden, depression and HR-QoL. 
We aimed to address the following research questions: 
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METHODS 
Study design and setting 
We conducted a descriptive, observational, cross-sectional study. We recruited a convenience sample 
of patients with lung cancer from two NHS Health Boards in Scotland, and within these Boards, 
recruitment took place at six regional hospitals. Reporting of the study was guided by the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement (Von 
Elm et al., 2014).  
Eligibility criteria 
Potential participants had to be: (a) aged ≥18 years; (b) have a clinical diagnosis of lung cancer; (c) 
able to understand study information; and (d) be physically and psychologically fit to participate as 
deemed by a member of the healthcare team. We excluded patients unable to meet any of the above 
criteria. 
Procedures 
The study received a favourable ethical opinion from the [Name of ethical committee.to be inserted 
here]. (Ref 14/EE/1099). Health professionals identified potential participants during routinely 
scheduled clinic visits. They briefly outlined the purposes of the study and provided a study pack 
which contained the patient information sheet, a consent form to be contacted for research interviews 
(details reported elsewhere), self-reported questionnaires, and a stamped envelope to return the 
completed pack anonymously to the researcher. Completion of the questionnaires acted as study 
consent. If the patient did not return the study packs within 14 days, a reminder letter was sent.  
Outcome measures 
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Cataldo Lung Cancer Stigma Scale (CLCSS). The CLCSS is a valid and reliable measure to assess the 
experiences of stigma (Cataldo et al., 2011). It comprises 31 items and four subscales (stigma and 
shame, social isolation, discrimination, and smoking) that are rated on a 4-point Likert scale (‘strongly 
disagree’, ‘disagree’, ‘agree’, ‘strongly agree’). A higher score indicates greater experience of stigma 
(possible score range 31-124). Cronbach’s alpha was 0.93. Construct validity was demonstrated with 
expected relationships with depression in our study as well as other studies (Cataldo et al, 2011, 
Gonzalez & Jacobson, 2012). 
Lung Cancer Symptom Scale (henceforth ‘LC symptom scale’). The LC symptom scale measures the 
severity of lung cancer specific symptoms, and has demonstrated good reliability and content validity 
(Hollen et al., 2005). The scale has 9 items (rated from 0-100), that measure symptoms, symptom 
burden and symptom severity. Higher scores indicate greater symptom severity. Cronbach’s alpha 
was 0.84. 
Centre for Epidemiologic Studies-Depression Scale (CES-D). The CES-D is a widely used tool to 
assess depression, with established validity and reliability in a wide range of populations including 
cancer (Sheehan, Fifield, Reisine, & Tennen, 1995). Twenty items are rated on a 4-point scale. Higher 
scores indicate greater depression (score range 0-60). Cronbach’s alpha was 0.89. 
Quality of Life Inventory (QLI). The QLI has four subscales (physical, psychological, social, and 
spiritual) and consists of 33 items (Ferrell, Wisdom, & Wenzl, 1989). This measure was previously 
validated with a population with LC (Sarna et al, 2005). Higher scores indicate better HR-QoL (score 
range 0-10). Cronbach’s alpha was 0.91. 
We collected self-reported socio-demographic information (e.g. smoking history), and clinical data 
from case note review, including lung cancer type and stage, presenting symptoms, mode of 
presentation, date of diagnosis, time since being diagnosed, previous treatment for lung cancer, 
current management/treatment of lung cancer, and any comorbidities.  
Data Analysis 
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We first investigated the factor structure of the CLCSS in our sample to account for any cultural 
diversity compared to the original factor structure based on US-based data (Cataldo et al., 2011). 
Compared to Cataldo et al., 2011 who reported a 4 factor structure (Stigma and Shame, Social 
Isolation, Discrimination, and Smoking), our analyses resulted in 5 factors (Social Isolation, Smoking, 
Stigma and Shame, Healthcare provider Stigma, Discrimination) (Table 1). The number of items in 
the scale per factor are reported in Table 1. (see Supplementary file 1 for details).  
Descriptive statistics and graphs were used to analyse CLCSS data. Frequency counts and percentages 
of responses were generated to describe response patterns and quantify missing data. Total and 
subscale CLCSS scores were treated as interval-ratio variables and are presented as means, standard 
deviation and range. 
Bivariate associations were explored between socio-demographic characteristics and clinical factors 
(interval-ratio or categorical), and all patient outcome variables (interval-ratio). Relationships between 
variables were determined using two samples t-test, one-way analysis of variance, or correlation 
coefficient calculation. Relationships among patient outcome variables were tested through 
correlation analysis. The functional form of these relationships and any necessary transformations 
were explored and assumptions of normality checked.  
Socio-demographic characteristics and clinical factors statistically significantly associated with 
patient outcome variables were retained and their effects controlled for in subsequent hierarchical 
regression modelling to investigate: (a) the effects of lung cancer symptom burden on perceived LCS, 
and (b) the effects of perceived LCS on depression and HR-QoL after controlling for significant 
socio-demographic and clinical covariates identified in the previous step. Assumptions relating to the 
normal distribution of errors and multicollinearity were investigated; no modifications to the analysis 
were required. Cumulative R2 and R2 change (ΔR2) was reported for each model to indicate the unique 
contribution of each predictor variable in explaining the variance of each dependent variable. The 
level of significance was set at 0.05. IBM SPSS (IBM Inc. Chicago, IL) was used for the statistical 
analysis. 
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RESULTS 
From 368 potential participants approached, 201 (54.6%) returned questionnaire packs. Case notes 
were accessible and reviewed for 195 participants. The total sample had a mean age of 69.2±9.1 years 
(range 41-89 years), 52% were women, 63.5% were married/partnered, and 71.2% were in a 
cohabitating situation (Table 2). Ninety-five percent were ever-smokers, 18.5% current smokers, and 
76.9% were quitters. The majority of participants had localised lung cancer (51.9%), non-small cell 
lung cancer (91.2%), and received surgery alone or in combination with systemic treatment (49.7%). 
Prevalence of LCS, symptom severity/burden, depression and HR-QoL deficits 
CLCSS score was 53.1 (SD=14.1; Table 1). Perceptions of LCS more frequently reflected eight 
CLCSS items/statements, endorsed by at least 20% of the sample (Figure 1). Most frequently, 
respondents agreed/strongly agreed that others assumed that lung cancer was caused by smoking even 
if the patient had stopped smoking years ago (61.7%) or never smoked at all (55.2%). Just over half 
the respondents ‘agreed’/’strongly agreed’ that lung cancer is viewed as a self-inflicted disease 
(51.2%). Eighteen per cent revealed that others had told them that being diagnosed with lung cancer 
was what they deserved for smoking. One in five respondents agreed that they felt guilty for having 
lung cancer (20%), and felt the need to hide their lung cancer (20%).  Nearly a quarter of participants 
(23.9%) believed that older people are less likely to be blamed for lung cancer compared to younger 
ones, that health professionals do not take smoker’s cough seriously (26.9%) and that they put off 
seeking medical help because they were afraid (23.9%). 
Symptom burden and symptom severity were low (mean: 31.1, 21.9) (Table 3). Shortness of breath 
and fatigue were on average reported as the most severe symptoms, followed by appetite loss and 
cough. Over half (55.2%) of respondents met the criteria for clinical depression (score >16). HR-QoL 
was moderate to good on average. 
Relationships among study variables 
9 
Positive correlations were demonstrated with depression, symptom burden, and all lung cancer 
symptoms except for appetite loss (Table 4). A moderate-to-strong negative correlation of perceived 
LCS with overall HR-QoL and all HR-QoL sub-domains was found. 
Negative correlations between LCS scores and sociodemographic variables were found with age, 
(Table 4). Positive correlations with LCS scores were observed for unemployed/homemaker status, 
and deprivation index. Although not statistically significant, current smokers reported on average 
greater perceived LCS than people who were not currently smokers. 
We identified significant relationships of higher levels of depression with younger age, female gender, 
living alone, being unemployed or homemaker, having a low annual income, being a smoking non-
quitter or a current smoker, lower HR-QoL and higher symptom burden (Table 4).  
Significant relationships of poorer HR-QoL with younger age, being unemployed or a homemaker, 
being a smoking quitter or a current smoker, being symptomatic prior to lung cancer diagnosis, having 
received radiotherapy, higher depression levels, and higher symptom burden were found. 
Symptom burden as a predictor of greater perceived LCS 
Accounting for the effects of age, employment status and social deprivation, hierarchical regression 
showed that the overall regression model of the second step was statistically significant with 18% of 
the variance in symptom burden being explained, F(4, 174)=9.24, p<0.001. More details are shown in 
Table 5. Incremental R2 for symptom burden was significant (ΔR2=0.05).  
Perceived LCS as a predictor of greater patient depression 
Accounting for the effects of covariates, hierarchical regression showed that the overall regression 
model of the third step was statistically significant with 22% of the variance in depression being 
explained, F(8, 138)=4.96, p<0.001 (Table 6). Socio-demographic characteristics explained 12.1% 
(p=0.006) of the total variance in depression, clinical factors explained 1.8% (p>0.05), and perceived 
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LCS contributed uniquely and significantly explaining 8.5% (p<0.001) of the total variance in 
depression.  
Perceived LCS as a predictor of lower patient HR-QoL 
Accounting for the effects of covariates, hierarchical regression showed that the overall regression 
model of the third step was statistically significant with 35% of the variance in HR-QoL being 
explained, F(6, 174)=15.36, p<0.001 (Table 6). Socio-demographic characteristics explained 14.4% 
(p<0.001), clinical factors explained 5.9% (p=0.005), and perceived LCS contributed uniquely and 
significantly explaining 14.3% (p<0.001) of the total variance in HR-QoL.  
DISCUSSION 
These findings support our hypotheses that greater perceived LCS can be directly associated with 
greater levels of depression and lower HR-QoL among patients with a lung cancer diagnosis. 
Moreover, we were able to confirm that symptom burden (but not symptom severity) can directly 
contribute to greater perceived LCS. These observations have clear implications for clinical practice 
and research. 
As in previous research (Brown Johnson, Brodsky, & Cataldo, 2014; Cataldo, Jahan, & Pongquan, 
2012; Lebel et al., 2013), analysis of CLCSS scores indicated that patients with lung cancer are 
vulnerable to stigmatisation after diagnosis, although in this study, mean LCS scores were below the 
mid-range of the scale. Other studies have shown CLCSS scores of 75-102 (vs 53.1 in this study) 
(Brown Johnson et al., 2014; Cataldo & Brodsky, 2013; Cataldo et al., 2012). This observation may 
indicate that the perceived LCS was generally low in this study’s sample. Low scores were also 
reported in two Australian samples of lung cancer patients with scores ranging from 52-55 (Rose et 
al., 2018; Chambers et al., 2015) and one American sample with a mean stigma score of 68 (Carter-
Harris et al., 2014). In these samples patients had a confirmed diagnosis of lung cancer and were 
either recruited via oncology clinics (Rose et al., 2018; Carter-Harris et al., 2014) or local support 
groups (Chambers et al., 2015). The participants in studies with high stigma scores recruited a 
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convenience sample via online cancer support websites, which could have influenced the LCS score 
because those participants may not be a typical lung cancer population.  
Rose et al. (2018) suggested that the LCS scores were low due to their sample being newly diagnosed 
with lung cancer. However, our sample was diagnosed on average 2.6 years prior to study 
Findings for the role of LCS as predictor for depression, and poorer HR-QoL in patients with lung 
cancer are consistent with the literature (Brown Johnson et al., 2014; Gonzalez & Jacobsen, 2012). 
Greater scores of stigma were predictive of higher levels of depression and poorer HR-QoL. This 
LCS did not return their questionnaires.  A recent study validated a new LCS tool to establish cut-off 
values to identify patients with clinically meaningful LCS (Ostroff et al., 2019). They found a value of 
37.5 (possible range of 25-125) and above to be clinically meaningful. The evidence is clear that 
perceived stigma is associated with poorer psychological well-being and therefore it is important that 
these patients receive intervention. Patients who only score high on a few items of the CLCSS 
resulting in an overall low score are still expressing perceptions of stigma. Thus, a lower score should 
also be recognised and those patients should be offered intervention. It is therefore important to 
establish a meaningful cut-point to identify patients in need for support. Future research could explore 
the cut-off points for the CLCSS which are clinically relevant for patients with LC. 
participation. It could be suggested that gender may contribute to the findings of different scores of 
stigma as those studies with higher scores had a higher proportion of women (Brown Johnson et al., 
2014; Cataldo & Brodsky, 2013; Cataldo et al., 2012). However, an Australian study that reported 
lower stigma scores had a higher proportion of men (Rose et al., 2018) and another study with an 
Australian sample had a higher proportion of women (Chambers et al., 2015). Both genders were 
evenly presented in this study making gender a less likely explanation. One factor that studies with 
lower stigma score had in common is the age of participants. In these studies, including the present 
study, participants’ mean age was 65-69years (Rose et al., 2018; Chambers et al., 2015). 
However, this observation should be interpreted with caution, as there is no consensus on what is low 
or high stigma using the CLCSS. It may also indicate that participants with high levels of perceived 
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Personalised care for patients with lung cancer who manifest perceived LCS is required. Our findings 
indicate that patients with poorer socioeconomic backgrounds have higher levels of LCS. While data 
population has been found to exhibit poorer psychological well-being than other cancer populations 
(Zabora, BrintzenhofeSzoc, Curbow, Hooker, & Piantadosi, 2001). The present findings assist in the 
identification of contributing factors to this high depressive symptomatology. Although only 8.5% of 
the variance in depression was explained by perceived LCS, this significant finding gives credence to 
the notion that the social implications and adverse social experiences of living with lung cancer can 
well build on patients’ feelings of low mood. It is possible that the longer patients live with perceived 
LCS, the greater the chances for them developing chronic depression.  
In addition to depression, we found that perceived LCS uniquely contributed to poorer HR-QoL. 
Further research is warranted to investigate a mediation path that leads from perceived LCS to 
depression and subsequently to HR-QoL, and investigate possible additional mediators such as social 
anxiety. Indeed, anxiety has previously been found to be related to higher levels of stigma (Brown 
Johnson et al., 2014; Cataldo & Brodsky, 2013). Anxiety as an additional stressor could further 
negatively affect health and increase the risk for stress-related illnesses (Link & Phelan, 2006).  
Attempting to identify the actual onset of perceived LCS, we identified a significant relationship 
between symptom burden and perceived LCS. Overt symptoms, such as cough, dyspnoea or 
haemoptysis may interfere with social interactions and lead to overt or covert reactions from others 
that may trigger experiences of LCS in patients with lung cancer. These relationships warrant future 
investigation. Interestingly, symptom severity did not make a significant contribution to perceived 
LCS over and above symptom burden. This may indicate that even mild symptoms, when manifested 
during social interactions and in everyday life (e.g. cough, dyspnoea), can be seen as a source of LCS 
for patients with lung cancer (Maguire, Stoddart, Flowers, McPhelim, & Kearney, 2014). These 
relationships have not been explored previously in people with lung cancer, but these findings may 
partly explain the higher perceived stigma in this group of patients compared to other cancers 
(Marlow, Waller, & Wardle, 2015).  
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on smoking rates across socioeconomic groups exist (Centers for Disease Control, 2008) the 
association with LCS has not been demonstrated. Stuber, Galea, and Link (2008) investigated the 
associations between smoking stigma and educational status. Their findings indicate that better 
socioeconomic background is associated with higher levels of smoking-related stigma. It is thought 
that people with social deprivation have more exposure to smoke-free laws (Barbeau, Krieger, & 
Soobader, 2004) thus leading to higher perceived stigma. Their participants were smokers and non-
smokers from New York City neighbourhoods answering a survey about relationships between 
neighbourhood characteristics and drug use. The design of their study (different measure, sample 
without LC) may explain the difference to our data. Further investigation of this relationship with LC 
patients is needed.  
We also found that younger patients are more likely to experience LCS. Older participants may feel 
less stigma due to the social acceptability of smoking when they first started smoking (Chapple et al., 
2004). We did not find a significant difference in perceived LCS between current and past smokers or 
non-smokers. Previous studies also failed to demonstrate a relationship between smoking status and 
LCS (Cataldo et al., 2012), which is in support of findings from qualitative research where 
participants reported LCS regardless of smoking status (Chapple et al., 2004). Smoking cigarettes is 
recognised as the main contributing risk factor for lung cancer, and national and international health 
policies have targeted the tobacco industry to attempt to reduce the burden of this disease. In doing so, 
this may have come with a cost; that these health policies lead to experiences of stigma in people 
diagnosed with lung cancer (Bell, Salmon, Bowers, Bell, & McCullough, 2010; Chapple et al., 2004; 
Stuber et al., 2008). Thus, it is likely that smoking history is irrelevant for experiences of perceived 
stigma if people with lung cancer are being queried about their smoking history by strangers, 
acquaintances or healthcare professionals after a diagnosis (Hamann et al., 2014). However, there is 
qualitative evidence that smoking history is relevant in the experience of internalized stigma (Hamann 
et al., 2014). It is likely that the small number of never-smokers in our study contributed to the lack of 
relationship. Associations between smoking status and depression, however, were significant, and this 
demonstrates that these patients have a need for care to address psychological morbidities, whether 
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this is related to the experience of stigma or not. Further research should be considered to investigate 
the role of smoking and the experience of stigma.  
In this study, we, as well as other research groups, have demonstrated that perceived LCS can 
originate from various sources and take various forms (Brown & Cataldo, 2013; Chapple et al., 2004; 
Hamann et al., 2014; Lehto, 2014; J. Weiss et al., 2017). Perceived stigma from healthcare 
professionals can be detrimental, as patients can feel discomfort communicating their symptoms to 
health professionals, which in turn can lead to delay in presentation, in diagnosis, and in treatment, or 
even low uptake of treatment (Corner, Hopkinson, & Roffe, 2006; Lehto, 2014; Tod, Craven, & 
Allmark, 2008). Supportive and empathetic communication is important to promote adherence to 
treatment (Zolnierek & DiMatteo, 2009). Furthermore, shame and blame can also lead to high levels 
of distress and depression amongst family members and partners (Milbury, Badr, & Carmack, 2012; 
Siminoff, Wilson‐Genderson, & Baker, 2010). Therefore, it is important not to exclude family 
members from such discussions, and to assess for the families’/carers’ own perceptions of LCS and 
how this may impact on their own feelings. It is thus important for health professionals to enter into 
sensitive discussions with patients and their families to explore the prevalence, nature and chronicity 
of LCS perceptions. 
Currently, interventions to reduce stigma among these patients are lacking, but individual counselling, 
or group interventions have been suggested to help the stigmatized to protect themselves from the 
impact of stigma, and reduce their vulnerability to encounters of stigmatization (M. G. Weiss, 
Ramakrishna, & Somma, 2006). In this group of patients, a combined intervention addressing 
depressive symptomatology and stigma should be considered because of the relationship between the 
two. A recent wellness intervention with patients with lung cancer, which was based on Cognitive 
Behaviour Therapy (CBT), focused on psycho-education, skills in stress reduction, problem-solving, 
cognitive challenging, and enhancing relationship support (Chambers, Morris, et al., 2015) and 
resulted in improvements in health-related stigma, as well as depression and cancer-specific distress 
(Chambers, Morris, et al., 2015).  
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Such interventions may also be delivered via the internet. Online CBT interventions have been studied 
in the context of mental health to treat for example depression, and anxiety (Andersson, 2009). 
Results demonstrate that such interventions can achieve similar outcomes as conventional face-to-face 
delivered therapies (Andersson, Cuijpers, Carlbring, Riper, & Hedman, 2014). Potential benefits of 
digital interventions could reduce health costs as less hours of therapists are required, but this largely 
depends on the design of the intervention (Fairburn & Patel, 2017). Furthermore, considering the 
stigma surrounding seeking help for mental health, the digital setting could overcome the barrier of 
low adherence to mental health treatments and increase its reach to people in need of psychological 
treatments (Muñoz et al., 2016).  
Strengths and Limitations 
In this study, we used a relatively large dataset from a patient sample from six hospitals and with 
diverse demographic and clinical characteristics that allowed for statistical examination of 
relationships among the multiple covariates. However, a large proportion of patients in this study 
received surgical treatment which is atypical for this population. Although we achieved a fairly high 
response rate, we are unable to make comparisons between respondents and non-respondents to 
identify potential bias in our sample and data. It is possible that people who did feel stigmatised in 
relation to their lung cancer diagnosis found the study of greater interest than those who had no LCS 
perceptions. Alternatively, those with experiences of LCS may have chosen not to participate.  
In addition, we did not collect information on additional covariates of potential interest, such as self-
esteem, self-efficacy, anxiety or treatment adherence. Therefore, future research should explore the 
above factors and their relationships with perceived LCS. Finally, this was a cross-sectional 
investigation of perceived LCS and covariates, which prevents us from establishing the “causal” 
pathways that involve precipitating and perpetuating triggers of LCS and its longitudinal impact on 
patient outcomes. Further longitudinal research is thus warranted. 
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Conclusions 
Perceived LCS is a significant predictor of poorer outcomes (symptom burden, depression, HR-QoL) 
in patients with lung cancer, when controlling for demographic and clinical variables. Perceived LCS 
is a potentially important psychosocial factor when considering the psychosocial well-being of 
patients with lung cancer. Incorporating systematic assessments of perceived LCS in the plan of care 
for patients with lung cancer is required to ensure adverse effects are tackled in a timely fashion at the 
time of diagnosis, during treatment and post-treatment. 
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Table 1 Descriptive statistics for the CLCSS total and component scores 
CLCSS Component (N=201) 
Mean (SD); 
Median 
Actual 
range 
Possible 
range 
Component 1 – Social Isolation 22.1 (7.6); 20.0 14-48 14-56
Component 2 – Smoking 7.6 (2.4); 8.0 3-12 3-12
Component 3 – Stigma and 
Shame 
12.6 (4.2); 12.0 8-26 8-32
Component 4 – Healthcare 
provider Stigma 
3.6 (1.5); 3.0 2-8 2-8
Component 5 – Discrimination 7.2 (2.3); 7.0 4-16 4-16
Scale 53.1 (14.1); 53.0 31-94 31-124
Note: CLCSS=Cataldo Lung Cancer Stigma Scale 
Table 2 Characteristics of all study participants (n=201) 
Variable Mean (SD); Median Min-Max 
Age in years (N=190) 69.2 (9.1); 70.5 41-89
Years since diagnosis (N=187) 2.6 (1.8); 1.9 0.2-11.0 
Variable N % 
Gender (N=196) 
Male 94 48.0 
Female 102 52.0 
Age categories (N=190) 
41-50 years 8 4.2 
N items 
14 
3 
8 
2 
4 
31 
23 
51-60 years 25 13.2 
61-70 years 62 32.6 
71-80 years 75 39.5 
>80 years 20 10.5 
Ethnicity (N=198) 
White 196 99.0 
Other 2 1.0 
Marital Status (N=200) 
Married/partnered 127 63.5 
Divorced/separated 24 12.0 
Widowed 36 18.0 
Single 13 6.5 
Living status (N=198) 
Alone 57 28.8 
With partner/family/friend 141 71.2 
Highest educational attainment (N=197) 
Primary school 28 14.2 
High school 122 61.9 
Higher Education College 33 16.8 
University 14 7.1 
Employment status (N=199) 
Employed (full-time/part-time) 24 (18/6) 12.0 
24 
Unemployed 17 8.5 
Retired 149 75.0 
Other (e.g. home maker) 9 4.5 
Annual income in £ (N=164) 
<10,000 64 39.0 
10,001-20,000 65 39.6 
20,001-50,000 30 18.3 
>50,000 5 3.1 
Deprivation Index (SIMD)* (N=185) 
Fifth 1 (most deprived) 71 38.4 
Fifth 2 35 18.8 
Fifth 3 29 15.7 
Fifth 4 24 13.0 
Fifth 5 (least deprived) 26 14.1 
Smoking status (N=195) 
Ever smoker 185 94.9 
Smoking quitter 150 76.9 
Current smoker 36 18.5 
Never-smoker 10 5.1 
Symptomatic prior to diagnosis (N=199) 
Yes 153 76.9 
Presentation (N=195) 
25 
GP 151 77.4 
Emergency 8 4.1 
Incidental 36 18.5 
Suspected Asbestos exposure (N=197) 36 18.3 
Disease status (N=183) 
Local 95 51.9 
Locally advanced 52 28.4 
Metastatic 31 16.9 
Not staged 5 2.8 
Treatment (N=195) 
Surgery only 62 31.8 
Surgery in combination with other 
treatment 
35 17.9 
Chemotherapy 87 44.6 
Radiotherapy 74 37.9 
No. of comorbid illnesses (N=188) 
None 40 21.3 
One 83 44.1 
Two 44 23.4 
Three or more 21 11.2 
Notes: SD=Standard Deviation; ‘Local disease’ is defined as any tumour that has not spread to the 
nodes; ‘Locally advanced’ is defined as the spread to lymph nodes; ‘Metastatic’ is defined as 
disease that is not localised and has spread to other parts of the body. 
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*http://assign-score.com/estimate-the-risk/simd/
Table 1. Descriptive statistics for depression, symptom burden, and HR-QoL 
Variable (N=201) Mean (SD); 
Median 
Actual range Possible range 
Depression 16.2 (10.9); 14.0 0-48 0-60
Symptom Overall score 32.1 (18.0); 31.6 0-84 0-100
Symptom Burden Index 31.1 (17.2); 29.7 0-85 0-100
Symptom Severity 21.9 (5.4); 22.0 16-89 0-100
Individual Symptoms 
Appetite loss 31.9 (26.9); 27.0 0-96 0-100
Fatigue 49.1 (28.3); 49.0 0-100 0-100
Cough 29.5 (28.5); 21.0 0-100 0-100
Shortness of breath 49.2 (32.1); 51.0 0-100 0-100
Haemoptysis 4.8 (12.5); 1.0 0-83 0-100
Pain 23.0 (29.2); 8.0 0-100 0-100
Quality of life 
Overall score 5.8 (1.4); 5.8 0-9 0-10
Physical 6.5 (1.8); 6.4 1-10 0-10
Psychological 5.5 (1.7); 5.6 0-10 0-10
Social 6.7 (1.9); 7.0 0-10 0-10
Spiritual 4.7 (2.1); 4.4 0-10 0-10
Notes: LCS=LC Stigma, HR-QoL=health-related quality of life 
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Table 2. Relationships among the study variables 
Variable LCS Depression HR-QoL 
Age (N=190) r=–0.28** r=–0.19* r=0.35** 
Time since diagnosis (N=187) r=0.09 r=0.17 r=–0.02 
Gender (N=196) t=0.08 t=–2.22* t=0.93 
Marital status (N=200) F=1.15 F=1.93 F=0.75 
Living status (N=198) t=0.97 t=2.95** t=–1.23 
Highest educational attainment (N=197) F=0.57 F=0.61 F=0.02 
Employment status (N=199) F=8.81*** F=6.88** F=13.51*** 
Annual income (N=164) F=0.52 F=4.18* F=2.28 
Deprivation Index (SIMD) (N=185) t=2.23* t=1.50 t=–0.79 
Ever smoker (N=195) t=0.91 t=1.18 t=–0.97 
Smoking quitter (N=195) t=–1.64 t=–3.43** t=3.00** 
Current smoker (N=194) t=1.81 t=3.56*** t=–3.12** 
Symptomatic prior to diagnosis (N=199) t=0.20 t=0.66 t=–1.98* 
Presentation (N=195) F=0.43 F=0.26 F=1.02 
Asbestos exposure (N=197) t=0.43 t=–1.09 t=1.08 
Localised disease (N=183) t=–1.55 t=–0.65 t=1.83 
Locally advanced (N=183) t=1.20 t=0.25 t=–1.22 
Metastatic disease (N=183) t=0.59 t=0.56 t=–0.93 
Surgery only (N=195) t=–0.32 t=–0.98 t=1.84 
Surgery in combination with other treatment 
(N=195) 
t=0.75 t=0.42 t=–0.35 
Chemotherapy (N=195) t=0.68 t=0.68 t=–1.18 
Radiotherapy (N=195) t=0.64 t=0.90 t=–2.04* 
No. of comorbid illnesses (N=188) F=0.94 F=0.17 F=0.25 
Quality of life (N=201) 
Overall score r=–0.52*** r=–0.69** -
28 
Physical r=–0.32*** r=–0.61** - 
Psychological r=–0.49*** r=–0.65** - 
Social r=–0.52*** r=–0.58** - 
Spiritual r=–0.18** r=–0.16** - 
Depression (N=201) r=0.40*** - r=–0.69** 
Symptom Overall score (N=201) r=0.29*** r=0.67** r=–0.67** 
Symptom Burden Index (N=201) r=0.26*** r=0.64** r=–0.61** 
Symptom Severity (N=201) r=0.07 r=0.10 r=–0.07 
Individual Symptoms 
Appetite loss (N=201) r=0.14 r=0.47** r=–0.42** 
Fatigue (N=201) r=0.21*** r=0.56** r=–0.53** 
Cough (N=201) r=0.19*** r=0.34** r=–0.31** 
Shortness of breath (N=201) r=0.15* r=0.38** r=–0.40** 
Haemoptysis (N=201) r=0.19*** r=0.26** r=–0.21** 
Pain (N=201) r=0.16* r=0.46** r=–0.46** 
Table 5. Summary of hierarchical regression analysis for symptom burden predicting LCS 
Step Predictor β ΔR2 
1 Socio-demographic characteristics 0.13*** 
Age –0.23**
Unemployed or home maker 0.11 
Most deprived socioeconomic area –0.12
2 Patient outcome variables 0.05*** 
Notes: LCS=LC Stigma; GP=General Practitioner; QoL=Quality of Life;SIMD=Scottish Index of 
Multiple Deprivation, ‘Local disease’ is defined as any tumour that has not spread to the nodes; 
‘Locally advanced’ is defined as the spread to lymph nodes; ‘Metastatic’ is defined as disease that 
is not localised and has spread to other parts of the body. *p<0.05; **p<0.01; ***p<0.001 
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Symptom burden index 0.22*** 
Cumulative R2 0.18*** 
Dependent variable: LCS 
Notes: Betas shown are for the last step; Employment status was coded as a binary variable 
(unemployed/home maker v. employed/retired); Social deprivation was coded as a binary 
variable (1st fifth v. all other). 
*p<0.05; **p<0.01; ***p<0.001
Table 6. Summary of hierarchical regression analysis for LCS predicting depression and QoL 
Regression 1 - Dependent variable: Depression 
Step Predictor β ΔR2 
1 Socio-demographic characteristics 0.12** 
Age –0.07
Female 0.16* 
Living alone –0.11
Unemployed or home maker –0.01
Earning <£10,000 annually 0.20 
Earning £10,001-20,000 annually 0.12 
2 Clinical factors 0.02 
Current smoker –0.15
3 Patient outcome variables 0.09*** 
Perceived LCS 0.31*** 
Cumulative R2 0.23*** 
Regression 2 - Dependent variable: QoL 
Step Predictor β ΔR2 
1 Socio-demographic characteristics 0.14*** 
Age 0.15* 
Unemployed or home maker –0.10
2 Clinical factors 0.06** 
Current smoker 0.12 
Symptomatic prior to LC diagnosis 0.13* 
Previous radiotherapy 0.12 
3 Patient outcome variables 0.15*** 
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Perceived LCS –0.40***
Cumulative R2 0.35*** 
Notes: Betas shown are for the last step; Employment status was coded as a binary variable 
(unemployed/home maker v. employed/retired). 
*p<0.05; **p<0.01; ***p<0.001
Figure 1. Item-by-item prevalence of “agree” or “strongly agree” responses (indicating perceived LCS) on 
the LCSS. 
